Tryp Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial for the Treatment of Fibromyalgia at The University of Michigan Life Science Investing
Emyria’s Specialist Psychiatrist Granted Authorised Prescriber Status in MDMA-Assisted Therapy for PTSD Life Science Investing
Cardiol Therapeutics Announces it has Exceeded 50% Enrollment in its Phase II ARCHER Trial in Acute Myocarditis Geography
Court of Appeals for the Federal Circuit Hears Oral Arguments on Patent Dispute Pharmaceutical Investing
PRINCIPAL TECHNOLOGIES CLOSES SECOND TRANCHE AND ANNOUNCES UPSIZE OF OVERSUBSCRIBED PRIVATE PLACEMENT Geography
Bausch Health Announces Positive Topline Results From Global Phase 2 Study Evaluating Amiselimod to Treat Ulcerative Colitis Pharmaceutical Investing
Knight Therapeutics Enters into Exclusive License Agreement with Supernus Pharmaceuticals for Qelbree® in Canada Pharmaceutical Investing
